Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study

Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study

Abstract Background Advanced lung adenocarcinoma patients often develop resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs), leaving uncertainties regarding subsequent treatment strategies. Although personalized therapy targeting individual acquired resistances (ARs) shows promise, its efficac...

Full description

Bibliographic Details
Main Authors: Kan Jiang, Lin Wu, Xinlong Zheng, Yiquan Xu, Qian Miao, Xiaobin Zheng, Longfeng Zhang, Cheng Huang, Gen Lin
Format: Article
Language:English
Published: BMC 2024-02-01
Series:BMC Pulmonary Medicine
Subjects:
Non‐small cell lung cancer
EGFR-TKI resistance
Chemotherapy
Personalized therapy
Online Access:https://doi.org/10.1186/s12890-024-02905-1

Internet

https://doi.org/10.1186/s12890-024-02905-1

Similar Items